Palisade Bio presents preclinical data of PALI-2108

Palisade Bio (PALI) announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific phosphodiesterase-4 inhibitor prodrug is in development for patients with ulcerative colitis. Key Highlights: PALI-2108 reduced colitis symptoms in mice without causing CNS toxicity, suggesting it could be a novel treatment for UC. It effectively converts to the active PDE4 inhibitor, PALI-0008, in the colon following oral administration in mice, dogs, and humans. PALI-2108 showed superior potency and target engagement in preclinical studies compared to other PDE4 inhibitors. It demonstrated dose-dependent efficacy in a mouse UC model, outperforming standard treatments. No systemic safety issues were observed in mice, dogs, or monkeys. PK modeling supports twice-daily dosing during induction and once-daily during maintenance, leveraging the drug’s extended-release properties. PALI-2108 exhibited a favorable therapeutic window, with higher tissue-to-plasma ratios and enhanced tissue inhibition in preclinical studies compared to other PDE4 inhibitors.